In vitro activity of isavuconazole against Trichosporon, Rhodotorula, Geotrichum, Saccharomyces and Pichia species

Journal of Antimicrobial Chemotherapy

Volumn 64, Issue 1, 2009, Pages 79-83

  Thompson III, George R ^a,b   Wiederhold, Nathan P ^a,b,c   Sutton, Deanna A ^d   Fothergill, Annette ^d   Patterson, Thomas F ^a,b  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

^c UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^d Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

Blastoschizomyces capitatum; MICs; Rare yeasts; Triazoles

Indexed keywords

AMPHOTERICIN B; FLUCONAZOLE; FLUCYTOSINE; ISAVUCONAZOLE; POSACONAZOLE; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CONTROLLED STUDY; DRUG SENSITIVITY; GEOTRICHUM; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PICHIA; RHODOTORULA; SACCHAROMYCES; SPECIES COMPARISON; TRICHOSPORON;

ANTIFUNGAL AGENTS; FUNGI; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOSES; NITRILES; PYRIDINES; TRIAZOLES;

EID: 67249103186     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkp138     Document Type: Article

References (10)

1. Walsh TJ, Groll A, Hiemenz J et al. Infections due to emerging and uncommon medically important fungal pathogens. Clin Microbiol Infect 2004; 10 Suppl 1: 48-66.
2. Paphitou NI, Ostrosky-Zeichner L, Paetznick VL et al. In vitro antifungal susceptibilities of Trichosporon species. Antimicrob Agents Chemother 2002; 46: 1144-6.
3. Cornely OA. Aspergillus to Zygomycetes: Causes, risk factors, prevention, and treatment of invasive fungal infections. Infection 2008; 36: 296-313.
4. Diekema DJ, Petroelje B, Messer SA et al. Activities of available and investigational antifungal agents against Rhodotorula species. J Clin Microbiol 2005; 43: 476-8.
5. D'Antonio D, Mazzoni A, Iacone A et al. Emergence of fluconazole-resistant strains of Blastoschizomyces capitatus causing nosocomial infections in cancer patients. J Clin Microbiol 1996; 34: 753-5.
6. Guinea J, Pelaez T, Recio S et al. In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of Zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species. Antimicrob Agents Chemother 2008; 52 1396-400.
7. National Committee for Clinical Laboratory Standards. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts: Approved Standard M27-A2. NCCLS, Wayne, PA, USA, 1997.
8. Pfaller MA, Diekema DJ. Rare and emerging opportunistic fungal pathogens: Concern for resistance beyond Candida albicans and Aspergillus fumigatus. J Clin Microbiol 2004; 42: 4419-31.
9. Martino R, Salavert M, Parody R et al. Blastoschizomyces capitatus infection in patients with leukemia: Report of 26 cases. Clin Infect Dis 2004; 38: 335-41.
10. Thompson GR III, Wiederhold NP, Fothergill AW et al. Antifungal susceptibilities among different serotypes of Cryptococcus gattii and Cryptococcus neoformans. Antimicrob Agents Chemother 2009; 53: 309-11.